Table 1.
Characteristic | N (%) |
Median age at study entry | 53 (IQR 43–62) |
Gender (female/male) | 8 (67)/4 (33) |
Race (Caucasian/non-Caucasian) | 11 (92)/1 (8) |
Site (colon/rectum) | 10 (83)/2 (17) |
Stage | |
IIIA | 1 (8) |
IIIB | 8 (67) |
IIIC | 3 (25) |
Adjuvant therapy | |
Chemotherapy | 10 (83) |
Chemotherapy and radiotherapy | 2 (17) |
Time from surgery to study enrollment (months) | 10.5 (IQR 8.8–11.3) |
CEA, carcinoembryonic antigen; VRP, virus-like replicon particle.